'Antibody Profiles and Genetics of Pernio-Like Lesions during the COVID-19 pandemic'

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3K23AI136579-03S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2021
  • Known Financial Commitments (USD)

    $53,860
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Esther E Freeman
  • Research Location

    United States of America
  • Lead Research Institution

    Massachusetts General Hospital
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project SummaryA subset of patients with coronavirus disease-2019 (COVID-19) develop cutaneous manifestations of theirsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including pernio of their feet andhands, known as "COVID toes." These patients tend to have a mild disease course, which may indicatesuccessful viral control by the host. By leveraging an existing patient cohort at Massachusetts General Hospital(MGH), and the extensive laboratory infrastructure at the NIH, this proposal aims to elucidate the complexdeterminants of a unique phenotype of COVID-19: pernio/ "COVID toes," with the following Aims. Aim 1: Toevaluate genetic determinants of pernio-like lesions ("COVID toes") in response to SARS-CoV-2 infection. Aim2: To characterize the inflammatory and serological response during acute infection and convalescence ofpatients with SARS-CoV-2 who develop pernio-like lesions as a symptom of COVID-19. Biological samples willbe obtained at MGH and sent to collaborating labs at the NIH. In particular, this proposal will help usunderstand the host immune response to COVID-19 by focusing on patients who have controlled the diseaseand have had relatively mild clinical courses, as characterized by their skin lesions. Successful completion ofour aims will immediately and directly respond to important gaps in our knowledge regardingmild/asymptomatic COVID-19, which in turn can help inform our understanding of how to harness this type ofsuccessful control for other patients.